From April 15 to 18, 2013, the U.S. FDA officials site inspected our products: Tobramycin, Mycophenolic acid, Amikacin for a period of four days on GMP compliance. At the summary of the meeting, prosecutors affirmed that Daxin Pharmaceutical had done a good job on GMP compliance, and they did not found any non-compliance events and phenomena. And all agreed that Chongqing Daxin passed the inspection.